Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of CA-002 for the treatment of peanut allergies: A randomized, double-blind, placebo-controlled study

Trial Profile

A phase III trial of CA-002 for the treatment of peanut allergies: A randomized, double-blind, placebo-controlled study

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CA 002 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Camallergy
  • Most Recent Events

    • 06 Nov 2019 According to a Camallergy media release, the company plans to initiate a randomized, double-blind, placebo-controlled Phase 3 clinical trial by mid-year 2020.
    • 26 Oct 2018 New trial record
    • 17 Oct 2018 According to a Camallergy media release, this trial is planned for the year 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top